Stock Analysis

Need To Know: Analysts Are Much More Bullish On Inventiva S.A. (EPA:IVA)

Inventiva S.A. (EPA:IVA) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with the analysts modelling a real improvement in business performance.

After this upgrade, Inventiva's ten analysts are now forecasting revenues of €19m in 2025. This would be a huge 26% improvement in sales compared to the last 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 69% to €0.60. However, before this estimates update, the consensus had been expecting revenues of €14m and €0.80 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

See our latest analysis for Inventiva

earnings-and-revenue-growth
ENXTPA:IVA Earnings and Revenue Growth April 2nd 2025

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 26% growth on an annualised basis. That is in line with its 23% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 23% annually. So although Inventiva is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.

Advertisement

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Inventiva is moving incrementally towards profitability. There was also an upgrade to revenue estimates, although as we saw earlier, forecast growth is only expected to be about the same as the wider market. The clear improvement in sentiment should be enough to get most shareholders feeling more optimistic about Inventiva's future.

Analysts are definitely bullish on Inventiva, but no company is perfect. Indeed, you should know that there are several potential concerns to be aware of, including major dilution from new stock issuance in the past year. For more information, you can click through to our platform to learn more about this and the 2 other warning signs we've identified .

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTPA:IVA

Inventiva

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.

Slight risk and slightly overvalued.

Advertisement

Weekly Picks

AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
65 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
FU
FundamentallySarcastic
CCP logo
FundamentallySarcastic on Credit Corp Group ·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6410.4% overvalued
11 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Updated Narratives

BO
MU logo
BonSquid88 on Micron Technology ·

Micron Technology will experience a robust 16.5% revenue growth

Fair Value:US$40021.1% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
AMZN logo
MarketMuse on Amazon.com ·

Amazon will rebound as AI investments start paying off by late 2026

Fair Value:US$45049.7% undervalued
45 users have followed this narrative
2 users have commented on this narrative
0 users have liked this narrative
RO
Robbo
HVN logo
Robbo on Harvey Norman Holdings ·

Inside Harvey Norman: Asset-Heavy Retail in an Online World

Fair Value:AU$5.8419.5% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
65 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0225.4% undervalued
1011 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative